USFDA gives Orphan Drug Designation to Zydus for malaria treatment

The phase-I study of ZY19489 has demonstrated a long half-life and the potential for a single-dose cure for malaria.

105
USFDA
Picture: Pixabay

Zydus Cadila today received orphan drug designation from the US Food and Drug Administration (USFDA) for its antimalarial compound ZY19489 (MMV253), currently in development together with Medicines for Malaria Venture (MMV), a leading product development partnership (PDP) in antimalarial drug research, the company said via a statement.

The statement said that the orphan drug designation provides eligibility for certain development incentives, including tax credits for qualified clinical testing, prescription drug user fee exemptions, and seven-year marketing exclusivity upon USFDA approval.

The phase-I study of ZY19489 has demonstrated a long half-life and the potential for a single-dose cure for malaria.

In a separate malaria challenge trial, potent antimalarial activity has been demonstrated following single-dose oral administration of ZY19489, the statement mentioned.

Speaking on the development, Pankaj R. Patel, Chairman, Zydus Group, said, “As a global community facing threats from rapidly mutating malaria strains and the rise in artemisinin resistance cases, we have to be prepared with novel therapeutic drugs.

ZY-19489 is a potential single-dose radical cure for P. falciparum and P. vivax malaria which is a major global health risk today.”

“ZY19489 is a potent, first-in-class molecule, originally discovered and elaborated in India,” said Dr Timothy Wells, Chief Scientific Officer, MMV.

He added, “The drug has tremendous potential as part of a new generation of treatments and is fully active against drug-resistant strains of malaria, which are becoming an increasing concern.”

USFDA relaxes restriction on Abortion Pill

USFDA approved Finasteride, Tadalafil for new treatment for Benign Prostatic Hyperplasia

Govt notifies NIB, Noida as CDL to test Covid-19 vaccines

USFDA issues Form 483 to Alembic Pharma Gujarat plant

Pharma Manufacturing & Packaging Congress to be held in June 2022

USFDA approves generic drug for Blood Pressure

USFDA relaxes restriction on Abortion Pill

Medical Devices: Current scenario and need of the hour

Govt introduces amendment Bill, decriminalising use of biological resources by ‘Vaids’,…

USFDA approved Finasteride, Tadalafil for new treatment for Benign Prostatic Hyperplasia

Govt notifies NIB, Noida as CDL to test Covid-19 vaccines

USFDA issues Form 483 to Alembic Pharma Gujarat plant

FDA Haryana and police unearthed a unit manufacturing spurious cosmetics

In-service Pharmacists authorised to dispense drugs for these 8 common ailments

Recruitment of 87 Drug Inspectors put on hold in Maharashtra

Latest Notifications regarding Pharmaceuticals

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news

Enter your email address:

Delivered by FeedBurner